Jylamvo (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This inhibition reduces the production of nucleotides, limiting the replication of rapidly dividing cells such as immune‑activated lymphocytes and malignant tumor cells, thereby exerting immunosuppressive and anticancer effects.

The specific dose of Jylamvo is determined individually by the prescribing healthcare professional based on the patient’s condition, weight, renal function, and treatment goals. Dosage regimens can vary widely between indications, and adjustments are made according to clinical response and laboratory monitoring.

Methotrexate is generally contraindicated during pregnancy because it can cause fetal malformations and miscarriage. Women of child‑bearing potential should use effective contraception while on therapy. Limited data exist for breastfeeding, and the drug is usually avoided unless the benefits outweigh potential risks.

To place an order, submit an enquiry on the Jylamvo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Jylamvo is a generic oral formulation of methotrexate, offering the same active ingredient and pharmacologic profile as brand‑name equivalents. Compared with biologic agents, methotrexate is less expensive and administered orally, but it may have a broader side‑effect profile and requires regular laboratory monitoring.

Store Jylamvo tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Jylamvo is taken orally with a full glass of water, usually once weekly for many indications, although dosing frequency may differ based on the condition being treated. Patients should follow the prescribing physician’s instructions regarding timing, food intake, and any required folic acid supplementation.

Serious adverse events include liver toxicity, pulmonary fibrosis, and severe bone‑marrow suppression leading to pancytopenia. Patients should promptly report persistent abdominal pain, unexplained bruising or bleeding, shortness of breath, or yellowing of the skin or eyes, as these may signal life‑threatening complications.

Jylamvo is contraindicated in individuals with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in pregnant women. Caution is also advised for patients with pre‑existing blood disorders, uncontrolled diabetes, or those receiving other folate‑antagonist medications.